Search research articles
Contact Us
Filters
Showing results (181-190 of 219) with videos related to
Page
of 22
Sort By:
Journal of Crohn'S & Colitis
|
August 31, 2023
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension
Silvio Danese, Remo Panaccione, Maria T Abreu, et al.
Plos One
|
May 22, 2013
TLR4 activates the β-catenin pathway to cause intestinal neoplasia
Rebeca Santaolalla, Daniel A Sussman, Jose R Ruiz, et al.
Gastro Hep Advances
|
September 5, 2022
Lamina Propria Phagocyte Profiling Reveals Targetable Signaling Pathways in Refractory Inflammatory Bowel Disease
Gillian E Jacobsen, Irina Fernández, Maria A Quintero, et al.
Inflammatory Bowel Diseases
|
August 22, 2022
Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy
Maria T Abreu, Julie M Davies, Maria A Quintero, et al.
The Lancet. Gastroenterology & Hepatology
|
July 9, 2023
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting
Tommaso Lorenzo Parigi, Ferdinando D'Amico, Maria T Abreu, et al.
Inflammatory Bowel Diseases
|
October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Gastroenterology
|
December 28, 2020
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner, Amanda Ricciuto, Ayanna Lewis, et al.
Nature Communications
|
May 4, 2026
An IL-17-DUOX2 axis controls gastrointestinal colonization by Candida albicans
Pallavi Kakade, Juan F Burgueno, Shabnam Sircaik, et al.
Inflammatory Bowel Diseases
|
February 14, 2025
Deep Sequencing of Crohn's Disease Lamina Propria Phagocytes Identifies Pathobionts and Correlates With Pro-Inflammatory Gene Expression
Gillian E Jacobsen, Eddy E Gonzalez, Payton Mendygral, et al.
Inflammatory Bowel Diseases
|
March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Page
of 22
Search research articles
Search
Showing results (181-190 of 219) with videos related to
Sort By:
Page
of 22
Journal of Crohn'S & Colitis
|
August 31, 2023
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension
Silvio Danese, Remo Panaccione, Maria T Abreu, et al.
Plos One
|
May 22, 2013
TLR4 activates the β-catenin pathway to cause intestinal neoplasia
Rebeca Santaolalla, Daniel A Sussman, Jose R Ruiz, et al.
Gastro Hep Advances
|
September 5, 2022
Lamina Propria Phagocyte Profiling Reveals Targetable Signaling Pathways in Refractory Inflammatory Bowel Disease
Gillian E Jacobsen, Irina Fernández, Maria A Quintero, et al.
Inflammatory Bowel Diseases
|
August 22, 2022
Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy
Maria T Abreu, Julie M Davies, Maria A Quintero, et al.
The Lancet. Gastroenterology & Hepatology
|
July 9, 2023
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting
Tommaso Lorenzo Parigi, Ferdinando D'Amico, Maria T Abreu, et al.
Inflammatory Bowel Diseases
|
October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Gastroenterology
|
December 28, 2020
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner, Amanda Ricciuto, Ayanna Lewis, et al.
Nature Communications
|
May 4, 2026
An IL-17-DUOX2 axis controls gastrointestinal colonization by Candida albicans
Pallavi Kakade, Juan F Burgueno, Shabnam Sircaik, et al.
Inflammatory Bowel Diseases
|
February 14, 2025
Deep Sequencing of Crohn's Disease Lamina Propria Phagocytes Identifies Pathobionts and Correlates With Pro-Inflammatory Gene Expression
Gillian E Jacobsen, Eddy E Gonzalez, Payton Mendygral, et al.
Inflammatory Bowel Diseases
|
March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Page
of 22